“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

19 March 2019
Pharma

Visiongain has published a new pharma report Global Asthma & COPD Therapies Marke Report : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period.

Despite approaching maturity, there remain several unmet needs in the market. In particular, COPD has long been ignored both by medical practitioners, the general public and also the pharmaceutical industry. As the disease is predicted to become the third-leading cause of death by 2030, this will be an area in which novel therapeutics may bring in significant revenue.

The asthma market is becoming highly competitive and fragmented, but there remain significant areas with unmet needs. Pharmaceutical companies will depend on life cycle management strategies in the immediate future to maintain profits with newer pipeline products becoming available over the forecast period.

The lead analyst commented that "Recent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed. The studies suggest that varying genotypes and phenotypes lead to different patients reacting differently to the same drug. This will drive demand for personalised therapies targeting the needs of each patient subgroup. Drugs paired with tests for biomarkers could become more frequent in the R&D pipeline going forward."

Leading companies featured in this report include AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Roche, Teva and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biobanking Market Report 2021-2031

In clinical trials relating to COVID-19, COVID-19 biobanks will play an important role. These biobanks will play an instrumental role in future scientific studies on the emerging coronavirus (COVID-19) pandemic facing the world.

23 October 2020

Read

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

Read

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

Read

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever